Irish medicines body announces 2009 fee increase
This article was originally published in RAJ Devices
Executive Summary
The Irish Medicines Board (IMB) has launched a consultation process on the level of its 2009 fees, proposing their overall increase by 4.9%. “It is essential that increasing costs, arising from issues outside the IMB’s direct control be reflected in an increased fee income to enable it to meet and enhance our service levels to client companies,” the authority has noted.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.